Get the Stockscreener App
2.17
1.36%
-0.03
Qualigen Therapeutics Inc stock is traded at $2.17, with a volume of 33,276.
It is down -1.36% in the last 24 hours and down -34.64% over the past month.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
See More
Previous Close:
$2.20
Open:
$2.2
24h Volume:
33,276
Relative Volume:
0.04
Market Cap:
$3.55M
Revenue:
$4.79M
Net Income/Loss:
$-13.42M
P/E Ratio:
-0.8158
EPS:
-2.66
Net Cash Flow:
$-10.30M
1W Performance:
-22.50%
1M Performance:
-34.64%
6M Performance:
-33.64%
1Y Performance:
-81.54%
1-Day Range:
$1.9995
$2.2001
1-Week Range:
$1.9995
$2.9757
52-Week Range:
$1.9995
$12.11
Qualigen Therapeutics Inc Stock (QLGN) Company Profile
Name
Qualigen Therapeutics Inc
Sector
Industry
Phone
(760) 918-9165
Address
2042 CORTE DEL NOGAL, CALIFORNIA
Compare QLGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QLGN
Qualigen Therapeutics Inc
|
2.17 | 3.60M | 4.79M | -13.42M | -10.30M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Qualigen Therapeutics Inc Stock (QLGN) Latest News
Combining machine learning predictions for Qualigen Therapeutics Inc.Free Optimized Watchlist With Daily Adjustments - Newser
Full technical analysis of Qualigen Therapeutics Inc. stockSector-Wise Stock Strength Trend Analysis - Newser
How Qualigen Therapeutics Inc. stock performs during market volatilityIntraday Price Forecast Using Volume Models - Newser
What institutional investors are buying Qualigen Therapeutics Inc. stockPre Market Review For Consistent Profits - jammulinksnews.com
Can Qualigen Therapeutics Inc. Overcome Bearish SentimentShort Term High Yield Stock Tips for Active Traders - metal.it
Has Qualigen Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewReal Trader Watchlist of Hot Stocks Released - metal.it
Will Breakout in Qualigen Therapeutics Inc. Sustain Through Next WeekCapital Preserving Trade Plan Templates Shared - beatles.ru
Statistical indicators supporting Qualigen Therapeutics Inc.’s strengthFree Fast Gaining Stock Screener Report - Newser
Qualigen Therapeutics Secures Nasdaq Compliance Extension - MSN
Bollinger Band Squeeze Points to Volatility in Qualigen Therapeutics Inc.Weekly Chart Analysis With Entry Advice Provided - metal.it
Evaluating Qualigen Therapeutics Inc. with trendline analysisFree Low Risk Buy Zone Opportunity Watch - Newser
Is This the Dip to Buy in Qualigen Therapeutics Inc.Accurate Technical Trend Reversal Picks Detected - metal.it
Sector Leaders Rotate Capital Into Qualigen Therapeutics Inc.Real-Time Trade Insights Spark Market Reactions - metal.it
Qualigen Therapeutics Inc. Crosses 200 Day MA — Signal or NoiseTriple Return Setup With Risk Control Explained - metal.it
Is it the right time to buy Qualigen Therapeutics Inc. stockStock Market Entry Points To Watch Now - jammulinksnews.com
Qualigen Therapeutics Announces $4.5M Private Placement - MSN
Qualigen Therapeutics Granted Patents for Cancer Drug in More Than 20 European Countries - 富途牛牛
What makes Qualigen Therapeutics Inc. stock price move sharplyTop Performing Stock Insights Released Daily - metal.it
Qualigen's Strategic Turnaround and Nasdaq Compliance: A Credible Path to Long-Term Value - AInvest
Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status - The Manila Times
Qualigen Therapeutics' Nasdaq Compliance and Strategic Capital Raise: Assessing the Long-Term Viability of a Biotech in Crisis and Recovery - AInvest
Qualigen regains Nasdaq compliance with $4.5 million private placement - Investing.com Australia
Qualigen regains Nasdaq compliance with $4.5 million private placement By Investing.com - Investing.com India
Qualigen Secures Nasdaq Listing Status with $4.5M Strategic Funding, Addresses All Compliance Issues - Stock Titan
Published on: 2025-07-28 19:32:51 - metal.it
Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock - The Manila Times
Cancer Drug Developer Qualigen Secures $4.5M From Institutional Investors for Treatment Pipeline - Stock Titan
How many analysts rate Qualigen Therapeutics Inc. as a “Buy”Free Stock Selection - jammulinksnews.com
Combining machine learning predictions for Qualigen Therapeutics Inc. Long-Term Safety Investment Analysis Report - Newser
How volatile is Qualigen Therapeutics Inc. stock compared to the marketExceptional earning trajectories - jammulinksnews.com
What catalysts could drive Qualigen Therapeutics Inc. stock higher in 2025Unlock expert trading strategies for growth - jammulinksnews.com
How does Qualigen Therapeutics Inc. generate profit in a changing economyRapid return acceleration - jammulinksnews.com
Why is Qualigen Therapeutics Inc. stock attracting strong analyst attentionUnlock expert stock analysis and alerts - jammulinksnews.com
What are analysts’ price targets for Qualigen Therapeutics Inc. in the next 12 monthsAccelerated financial growth - jammulinksnews.com
What is Qualigen Therapeutics Inc. company’s growth strategyBuild a diversified portfolio for steady profits - jammulinksnews.com
Key External Factors That Drive Qualigen Therapeutics Inc. Stock Price MovementsLow Risk Consistent Winners - Newser
Competitive Positioning of Qualigen Therapeutics Inc.: Is It Leading or LaggingCapital Protected Stock Selections - Newser
Qualigen Therapeutics Inc. Stock Analysis and ForecastMassive portfolio appreciation - PrintWeekIndia
What drives Qualigen Therapeutics Inc. stock priceExplosive trading opportunities - PrintWeekIndia
What analysts say about Qualigen Therapeutics Inc. stock outlookTriple-digit wealth increases - jammulinksnews.com
What analysts say about Qualigen Therapeutics Inc. stockFree Predictions - jammulinksnews.com
Qualigen Therapeutics Inc Stock (QLGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):